Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice

INTRODUCTION: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody, approved for patients affected by chronic spontaneous urticaria resistant to antihistamines. Although the clinical benefit of omalizumab has been established in several clinical trials, there are very little data about...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollono, Laura, Piccolo, Arianna, Lanna, Caterina, Esposito, Maria, Bavetta, Mauro, Campione, Elena, Bianchi, Luca, Diluvio, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735630/
https://www.ncbi.nlm.nih.gov/pubmed/31564834
http://dx.doi.org/10.2147/DDDT.S214307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735630/
https://www.ncbi.nlm.nih.gov/pubmed/31564834
http://dx.doi.org/10.2147/DDDT.S214307

Ejemplares similares